摘要
母细胞性浆细胞样树突状细胞肿瘤(BPDCN)是一种罕见的侵袭性血液系统恶性肿瘤,异质性强,可累及皮肤、淋巴结和骨髓,预后不佳。目前,对BPDCN的治疗尚无统一标准,主要采用急性髓系白血病、急性淋巴细胞白血病和淋巴瘤为主的方案,针对化疗有很高的反应,但中位无事件生存期通常很短,一般不到两年。2018年,SL-401被批准为首个针对2岁及以上BPDCN患者的靶向治疗,靶向治疗的出现为患者的生存提供了希望。本文将重点探讨靶向治疗的优势及最新的思考。
Blastic plasmacytoid dendritic cell tumor(BPDCN)is a rare and invasive hematological malignancy with strong heterogeneity.It may involve the skin,lymph nodes and bone marrow,and has a poor prognosis.At present,there is no unified standard for the treatment of BPDCN,and the main regiments are acute myeloid leukemia,acute lymphoblastic leukemia and lymphoma.There is a high response to chemotherapy,but the median eventless survival time is usually very short,generally less than two years.In 2018,SL-401 was approved as the first targeted therapy for BPDCN patients aged 2 years and older,and the emergence of targeted therapy offers hope for patient survival.This article will focus on the advantages of targeted therapy and the latest thinking.
作者
王莹(综述)
许文婧
李转丽
杨柯
赵霄晨
白海(审校)
WANG Ying;XU Wen-jing;LI Zhuan-li;YANG Ke;ZHAO Xiao-chen;BAI Hai(Gansu University of Chinese Medicine,Lanzhou 730000,Gansu,CHINA;Deparment of Hematology,940 Hospital of PLA Joint Service Support Force,Lanzhou 730050,Gansu,CHINA)
出处
《海南医学》
CAS
2021年第14期1865-1869,共5页
Hainan Medical Journal
基金
国家自然科学基金(编号:81372132)
甘肃省自然科学基金(创新基地和人才计划)(编号:20JR5RA602)
甘肃省重大专项项目(编号:1102FKDA005)。
